article thumbnail

Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk

JAMA Cardiology

This genetic association study evaluates the association of genetic variants with atrial fibrillation, cardiomyopathy, and heart failure.

article thumbnail

Catheter ablation in patients with atrial fibrillation and dilated cardiomyopathy

Frontiers in Cardiovascular Medicine

Introduction Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n  = 27) had persistent atrial fibrillation.

article thumbnail

Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation.

HeartRhythm

Percutaneous left atrial appendage closure (LAAC) is an effective alternative strategy for stroke prevention in atrial fibrillation (AF) patients at high risk for bleeding with anticoagulation (AC). Efficacy of this strategy in hypertrophic cardiomyopathy (HCM) remains uncertain.

article thumbnail

PO-04-094 IMPROVED PREDICTION MODEL FOR RISK OF ATRIAL FIBRILLATION IN HYPERTROPHIC CARDIOMYOPATHY : LEAP-HCM SCORE

HeartRhythm

Atrial fibrillation(AF) is associated with increased risk of embolic stroke and heart failure hospitalizations in patients with hypertrophic cardiomyopathy(HCM).

article thumbnail

PO-03-086 FACTORS ASSOCIATED WITH CARDIAC FUNCTION IMPROVEMENT AFTER CATHETER ABLATION IN PATIENTS WITH SUSPECTED ATRIAL FIBRILLATION-MEDIATED CARDIOMYOPATHY

HeartRhythm

Catheter ablation is recommended in patients with suspected atrial fibrillation-mediated cardiomyopathy (AMC) for the recovery of cardiac function.

article thumbnail

PO-04-131 ATRIAL FIBRILLATION RECURRENCE FOLLOWING CATHETER ABLATION IS HIGHER IN HYPERTROPHIC COMPARED TO OTHER CARDIOMYOPATHY TYPES – INSIGHTS FROM LGE-MRI FIBROSIS

HeartRhythm

Atrial fibrillation (AF) is highly prevalent in patients with hypertrophic cardiomyopathy (HCM) as well as other cardiomyopathy (CM) phenotypes.

article thumbnail

Incidence of Newly Recognized Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten

HeartRhythm

Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM).1 1 In late-stage clinical trials, atrial fibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten.1,2